Patents for A61P 35 - Antineoplastic agents (221,099)
01/2007
01/18/2007WO2007006543A1 Camptothecin analogues, process for their preparation, use and formulations containing them
01/18/2007WO2007006459A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
01/18/2007WO2007006230A1 Process for preparing erianin
01/18/2007WO2007006211A1 Dipeptidyl peptidase iv (ddp iv) inhibitors, preparation methods and uses thereof
01/18/2007WO2007006117A1 Novel cyp2a6 inhibitors
01/18/2007WO2006128120A3 Novel lapachone compounds and methods of use thereof
01/18/2007WO2006124689A3 Combination therapy
01/18/2007WO2006108680A3 Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against protozoa and helminthes
01/18/2007WO2006105954A3 Use of an antibody against the laminin receptor or laminin receptor precursor for the treatment or diagnosis of several cancer types
01/18/2007WO2006081510A3 Methods for treating renal cell carcinoma
01/18/2007WO2006073748A3 Antibodies against antigen presenting cells and uses thereof
01/18/2007WO2006058869A8 Substituted pteridines for treating inflammatory diseases
01/18/2007WO2006058868A8 Substituted pteridines for treating inflammatory diseases
01/18/2007WO2006055526A3 Compositions useful to treat ocular neovascular diseases and macular degeneration
01/18/2007WO2006042104A3 Calixarene-based peptide conformation mimetics, methods of use, and methods of making
01/18/2007US20070016074 Contact lens for collecting tears and detecting analytes for determining health status, ovulation detection, and diabetes screening
01/18/2007US20070015907 Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions
01/18/2007US20070015819 Novel compounds
01/18/2007US20070015799 Glyoxalase inhibitors
01/18/2007US20070015797 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
01/18/2007US20070015775 Heterocyclic compounds
01/18/2007US20070015772 Nucleoside metabolism inhibitors
01/18/2007US20070015765 5-(2-pyrazinyl)-4methyl-1,2-dithiol-3-thione (Oltipraz) and its metabolites; neoplastic diseases, atherosclerosis, restenosis, rheumatoid arthritis, Crohn's disease, diabetic retinopathy, psoriasis, and endometriosis
01/18/2007US20070015756 For therapy of hyperproliferative diseases
01/18/2007US20070015755 Novel compounds and compositions as protease inhibitors
01/18/2007US20070015751 Nitro and amino substituted heterocycles as topoisomerase I targeting agents
01/18/2007US20070015743 Quinazoline derivatives as antitumor agents
01/18/2007US20070015723 Antiviral oligonucleotides having a conserved G4 core sequence
01/18/2007US20070015714 Methods for treating FSH related conditions with GnRH antagonists
01/18/2007US20070015269 Crystals of DPP-IV
01/18/2007US20070015239 Correlation between the fucose content/galactose content ratio of anti-rhesus-d and anti-hla-dr antibodies and the adcc activity
01/18/2007US20070015219 Specifically binds an MK61 polypeptide produced by immunizing an animal
01/18/2007US20070015197 Specific binding agents for KSHV vIL-6 that neutralize a biological activity
01/18/2007US20070014840 Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
01/18/2007US20070014798 Antibodies to dendritc cells and human dendritic cell populations and uses thereof
01/18/2007US20070014790 Transcription control factor zhx3
01/18/2007DE19782294B4 Nicht-Steroide Liganden für den Estrogenrezeptor Non-steroidal ligands for the estrogen receptor
01/18/2007CA2615291A1 Heterocyclic janus kinase 3 inhibitors
01/18/2007CA2614884A1 Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
01/18/2007CA2614696A1 Use of 4-(3,4-dichloro-phenyl)-1,2,3,4-tetrahydro-naphtalen-1-ylamine for treating cancer
01/18/2007CA2614531A1 Nucleic acid agents for downregulating h19, and methods of using same
01/18/2007CA2614320A1 Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
01/18/2007CA2612752A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents
01/18/2007CA2612506A1 Methods of treatment using hydroquinone ansamycins
01/18/2007CA2612442A1 Heterotetracyclic compounds as tpo mimetics
01/18/2007CA2612260A1 Apoptosis promoters
01/18/2007CA2612211A1 Modified poly(propylene-imine) dendrimers and their use as transfection agents for anionic bioactive factors
01/18/2007CA2603115A1 3-spirocyclopropyl2-oxindole kinase inhibitors
01/18/2007CA2602453A1 Kinase inhibitors
01/18/2007CA2602389A1 Kinase inhibitors
01/17/2007EP1743947A2 Method for diagnosing non-small cell lung cancers
01/17/2007EP1743901A2 Oligonucleotides having A-DNA or B-DNA form
01/17/2007EP1743891A1 Heterocyclic compounds and methods for modulating CXCR3 function
01/17/2007EP1743890A1 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
01/17/2007EP1743881A1 Phenyl-benzyl-ketones
01/17/2007EP1743657A2 Stabilisation of macrolides
01/17/2007EP1743654A1 Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases
01/17/2007EP1743651A1 Vaccine compositions which are obtained from streptomyces
01/17/2007EP1743648A1 Method for treating inflammation
01/17/2007EP1743632A1 Novel 4-dedimethy laminotetracycline derivatives
01/17/2007EP1742964A2 Peptide capable of altering tubulin polymerization and use thereof for inhibiting cell proliferation
01/17/2007EP1742952A1 (poly) aminoacetamide derivatives of epipodophyllotoxin, their process of preparation and their applications in therapeutics as anticancer agents
01/17/2007EP1742947A1 6-substituted pyridoindolone derivatives production and therapeutic use thereof
01/17/2007EP1742937A2 Pyrrolopyrimidine derivatives for treating proliferative diseases
01/17/2007EP1742920A2 Naphthalimide derivatives for the treatment of cancer
01/17/2007EP1742911A1 3,4-disubstituted maleimides for use as vascular damaging agents
01/17/2007EP1742907A2 Certain chemical entities, compositions, and methods
01/17/2007EP1742898A1 Metal complexes based on tetrathiol ligands and their use in nuclear medical diagnostics and endoradionuclide therapy and method for producing said metal complexes
01/17/2007EP1742650A1 Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors
01/17/2007EP1742644A2 Therapeutic compositions containing at least one pyrrolobenzodiazepine derivative and fludarabine
01/17/2007EP1742640A2 Methods and compositions for treating diseases and conditions associated with mitochondrial function
01/17/2007EP1742636A2 Preparation for the treatment cancer
01/17/2007EP1742623A2 2-methylthiazolidine-2,4-dicarboxylic acid-containing combination preparations
01/17/2007EP1742622A1 Use of ltb4 inhibitors for the treatment of b-cell leukemias and lymphomas
01/17/2007EP1546369A4 Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
01/17/2007EP1469868B1 Kurkumin composition for the cure of large intestine polyps
01/17/2007EP1453852B1 Selective urokinase inhibitors
01/17/2007EP1368474B1 Polynucleotide useful for modulating cancer cell proliferation
01/17/2007EP1337233B1 Use of at least a sulphonic amino derivative in a composition promoting skin peeling
01/17/2007EP1301539B1 Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
01/17/2007EP1272160B1 Lipid-based drug delivery systems for topical application
01/17/2007EP1268783B9 Antiangiogene Eigenschaften von Matin und Fragmenten oder Varianten davon
01/17/2007EP1268444B1 2,4-di(hetero-)arylamino(-oxy)-5-substituted pyrmidines as antineoplastic agents
01/17/2007EP1223977B1 Modified plant viruses and methods of use thereof
01/17/2007EP1140174B1 Antagonist antibodies of cutaneous t cell-attracting chemokine (ctack) or vasoactive intestinal contractor (vic) chemokines
01/17/2007EP1086207B1 Novel methods and interferon deficient substrates for the propagation of viruses
01/17/2007EP1076704B1 Il-2 selective agonists and antagonists
01/17/2007EP1070068B2 Granulatimide derivatives for use in cancer treatment
01/17/2007EP1063990B1 Use of a biochanin-enriched extract for the treatment of estrogen-associated disorders
01/17/2007CN1898268A Chimeric anti cd44 antibodies and their use for treating acute myeloid leukemia
01/17/2007CN1898267A 修饰的抗cd52抗体 Modified anti-cd52 antibody
01/17/2007CN1898262A Il-7 fusion proteins
01/17/2007CN1898240A Imidazopyrazine tyrosine kinase inhibitors
01/17/2007CN1898232A Maleate salts of a quinazoline derivative useful as an antiangiogenic agent
01/17/2007CN1898219A Novel keto-oxadiazole derivatives as cathepsin inhibitors
01/17/2007CN1898212A Analogs of benzoquinone-containing ansamycins for the treatment of cancer
01/17/2007CN1897971A Cd40 antibody formulation and methods
01/17/2007CN1897968A Method of treatment using interferon-tau
01/17/2007CN1897963A Use of cyclic anabaenopeptin-type peptides for the treatment of a condition wherein inhibition of carboxypeptidase u is beneficial, novel anabaenopeptin derivatives and intermediates thereof
01/17/2007CN1897951A Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune